GSK’s Nucala Gains EU Approval for COPD, Boosting Monday Stocks
On February 8, 2026, GSK secured approval from the European Commission for Nucala (mepolizumab) to treat chronic obstructive pulmonary disease (COPD) in adults. This important approval enables the wider use of Nucala among patients suffering from uncontrolled COPD with elevated blood eosinophils, even when existing treatments have failed.
Market Response and Stock Performance
Following the announcement, GSK’s stock saw positive movement. Shares closed at 2,198 pence, marking an increase of 0.8%. Over the past week, GSK’s stock has risen approximately 17% and boasts a nearly 49% surge over the last year. This growth elevates the company’s total valuation to nearly £88 billion.
Investor Insights
- GSK Chairman Jonathan Symonds purchased 2,500 shares at £21.14 each on February 5.
- This transaction amounted to £52,850.
- JP Morgan analyst Zain Ebrahim holds a “Sell” rating on the stock, with a target price of 1,700 pence.
Investors remain focused on upcoming dividend dates. GSK is set to go ex-dividend on February 19, with the record date on February 20. Payments are scheduled for April 9.
Clinical Trial Results
The approval of Nucala is founded on the positive results from the MATINEE phase 3 trial. This study highlighted substantial benefits for patients, showing a 21% reduction in the yearly rate of moderate or severe flare-ups, with a rate ratio of 0.79 compared to placebo. Additionally, flare-ups requiring emergency care or hospitalization decreased significantly, evidenced by a rate ratio of 0.65.
Expert Commentary
Kaivan Khavandi, GSK’s global head for Respiratory, Immunology & Inflammation R&D, noted that this marks the first time adults with uncontrolled COPD can access a monthly biologic treatment. However, Susanna Palkonen from the European Federation of Allergy and Airways Diseases Patients’ Associations pointed out the substantial challenges faced by COPD patients.
Future Outlook
As trading resumes, market participants will seek insights into how quickly Nucala can gain prescriptions following its approval. The EU decision could either enhance momentum for GSK’s stock or be seen as a minor step in a lengthy reimbursement journey across various countries. The uptake of biologic treatments for COPD may encounter scrutiny from payers, especially if conventional inhaler therapies remain the preferred option among physicians.
